ABSTRACT
The goal of the work toassessment of efficacy and safety of allergen immunotherapy in children and adults with allergic rhinitis, and to conduct a comparative assessment of the effectiveness of subcutaneous (SCIT) and sublingual variant (SLIT) immunotherapy. We have analyzed the medical documentation of patients during the application of allergen immunotherapy for 5 years in 710 patients with allergic rhinitis (AR). According to the results of the validated scale analysis, the clinical efficacy parameters of SCIT and SLIT after a year, 2, 3, and also after 4 and 5 years of therapy were comparable in both children and adults. At the same time, both SCIT and SLIT showed comparable efficacy in both adults and children. Systemic side effects were observed in 10% of children on SCIT and in 7% of children on SLIT. The frequency of systemic reactions in adults was 6% for SCIT, for SLIT it did not exceed 2%.
Subject(s)
Desensitization, Immunologic , Rhinitis, Allergic , Administration, Sublingual , Adult , Child , Humans , Injections, Subcutaneous , Rhinitis, Allergic/diagnosis , Rhinitis, Allergic/therapy , Treatment OutcomeABSTRACT
The purpose of study was to analyze own clinical experience and assess the effectiveness in treatment of severe very poorly controlled allergic asthma patients with omalizumab. The effectiveness of biologic treatment with omalizumab was analyzed in 10 patients with severe very poorly controlled allergic asthma. It has been shown that indication of anti-IgE therapy in case of severe allergic asthma resulted in decrease of day and night asthma symptoms, symptoms of allergic rhinitis, dose of other anti - inflammatory asthma medications, discontinuation of systemic corticosteroids which led to good and partial control of the disease. Anti-IgE therapy is a highly effective treatment in asthma patients with atopic phenotype.
Subject(s)
Anti-Asthmatic Agents/therapeutic use , Asthma/drug therapy , Omalizumab/therapeutic use , Antibodies, Monoclonal , Antibodies, Monoclonal, Humanized , Humans , Treatment OutcomeABSTRACT
Xymedone produced therapeutic effect in patients with atopic bronchial asthma. The drug action was manifested by a decrease in the IgE level and an increase in gamma-interferon level. Adding xymedone to lymphocytes cultivated with phytohemagglutinin revealed stimulating action of this drug on the delayed-type hypersensitivity. Mechanisms involved in the immunotropic action of xymedone are discussed.
